Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Solid Tumor|Clear Cell Renal Cell Carcinoma|TNBC - Triple-Negative Breast Cancer|Colorectal Cancer|CRC|RCC|ccRCC
Interventions: DRUG: CB-839|DRUG: Talazoparib
Sponsor: Calithera Biosciences, Inc